Popat Rakesh, Oakervee Heather E, Hallam Simon, Curry Nicola, Odeh Liz, Foot Nicola, Esseltine Dixie-Lee, Drake Mary, Morris Curly, Cavenagh Jamie D
Department of Haematology, St. Bartholomew's Hospital, London, UK.
Br J Haematol. 2008 May;141(4):512-6. doi: 10.1111/j.1365-2141.2008.06997.x. Epub 2008 Mar 26.
Bortezomib, doxorubicin and dexamethasone (PAD) was evaluated as induction before stem cell transplantation in newly diagnosed multiple myeloma (MM) patients, using bortezomib 1.3 mg/m(2) (PAD1, N = 21) or 1.0 mg/m(2) (PAD2, N = 20). Complete/very good partial response rates with PAD1/PAD2 were 62%/42% postinduction and 81%/53% post-transplant. Progression-free survival (29 vs. 24 months), time to re-treatment (36 vs. 29 months) and overall survival (1 year: 100% vs. 95%; 2 years: 95% vs. 73%) were statistically similar but favoured PAD1 versus PAD2. Toxicity was lower in PAD2; bortezomib dose reduction may help manage toxicities while retaining efficacy. PAD is highly active as front-line induction in MM.
硼替佐米、阿霉素和地塞米松（PAD）被评估用于新诊断的多发性骨髓瘤（MM）患者干细胞移植前的诱导治疗，使用硼替佐米1.3mg/m²（PAD1，N = 21）或1.0mg/m²（PAD2，N = 20）。诱导治疗后，PAD1/PAD2的完全缓解/非常好的部分缓解率分别为62%/42%，移植后的缓解率分别为81%/53%。无进展生存期（29个月对24个月）、再次治疗时间（36个月对29个月）和总生存期（1年：100%对95%；2年：95%对73%）在统计学上相似，但PAD1优于PAD2。PAD2的毒性较低；降低硼替佐米剂量可能有助于控制毒性同时保持疗效。PAD作为MM的一线诱导治疗具有高度活性。
Zotero 插件